Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability

NCT03452488 is registered in ClinicalTrials.gov with Biophytis as lead sponsor.

NCT NCT03452488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03452488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability
Lead sponsor
Biophytis
Phase
Phase 2
Overall status
Completed
Start date
February 7, 2017
Completion date
April 26, 2020
Enrollment
233 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

gait disorders in old age, muscle weakness, sarcopenia